# EDGAR Filing Document

**Accession Number:** 0000042872
**File Stem:** 0001104659-26-033489
**Filing Date:** 2026-3
**Character Count:** 10502
**Document Hash:** ae082b936ca6ccad8c0a0a99ce5109d0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-033489.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001104659-26-033489

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Humacyte, Inc.
- **CENTRAL INDEX KEY:** 0001818382
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851763759
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91701
- **FILM NUMBER:** 26784051

**BUSINESS ADDRESS:**
- **STREET 1:** 2525 EAST NORTH CAROLINA HIGHWAY 54
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27713
- **BUSINESS PHONE:** 919-313-9633

**MAIL ADDRESS:**
- **STREET 1:** 2525 EAST NORTH CAROLINA HIGHWAY 54
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27713

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alpha Healthcare Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200716
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
- **CENTRAL INDEX KEY:** 0000042872
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133461988
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** TWO LEDGEMONT CENTER
- **STREET 2:** 95 HAYDEN AVE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02420
- **BUSINESS PHONE:** 6174029000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FRESENIUS NATIONAL MEDICAL CARE HOLDINGS INC
- **DATE OF NAME CHANGE:** 19961015

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRACE W R & CO /NY/
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRACE W R & CO /CT/
- **DATE OF NAME CHANGE:** 19900423

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 007)**

**HUMACYTE, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Robert A. Grauman**<br>145 West 86 Street<br>New York NY 10024<br>646 202-2932

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/20/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fresenius Medical Care Holdings, Inc.** | Name of reporting person<br>**Fresenius Medical Care Holdings, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEW YORK** | Citizenship or place of organization<br>**NEW YORK** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**18312735.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**18312735.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**18312735.00** | Aggregate amount beneficially owned by each reporting person<br>**18312735.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.4%** | Percent of class represented by amount in Row (11)<br>**8.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fresenius Medical Care AG** | Name of reporting person<br>**Fresenius Medical Care AG** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**18312735.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**18312735.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**18312735.00** | Aggregate amount beneficially owned by each reporting person<br>**18312735.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.4%** | Percent of class represented by amount in Row (11)<br>**8.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
HUMACYTE, INC.

**(c) Address of Issuer's Principal Executive Offices:**
2525 East North Carolina Highway 54, Durham, NC, 27713

This Amendment No. 7 amends certain information contained in the Schedule 13D originally filed by Fresenius Medical Care Holdings, Inc., a New York Corporation ("FMCH") and Fresenius Medical Care AG a German stock corporation ("FME AG") on September 2, 2021, as previously amended by Amendment No. 1 filed December 1, 2023, Amendment No. 2 filed March 7, 2024, Amendment No 3 filed November 18, 2024, Amendment No 4 filed May 22, 2025, Amendment No 5 filed solely by FME AG on October 16 2025 and Amendment No. 6 filed by FME AG and FMCH on January 9;2026 (as so amended, the "Schedule 13D"), with respect to the common stock, par value $0.0001 per share (the "Common Stock") of Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare Acquisition Corp. (the "Issuer" or "Humacyte"). Capitalized terms not otherwise defined herein have the meanings set forth in the Schedule 13D. Except as provided herein, this Amendment No. 7 does not modify any of the information previously reported on the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
On the date of this Schedule 13D (Amendment No. 7), FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock, constituting approximately 8.4% of the Issuer's outstanding voting shares. Such percentage ownership is calculated by reference to 218,453,511 shares outstanding as of March 20, 2026, comprising (i) 187,727,321 shares outstanding as shown on the cover page of the Issuer's Form 10-Q filed November 12, 2025 plus (ii) 5,725,190 shares issued on December 15, 2025, as reported in the Issuer's Form 8-K filed that date, plus (iii) 25,000,000 shares issued on March 20, 2026, as reported by the Issuer in its Form 8-K report filed on March 19, 2026. All such 18,312,735 Shares are issued and outstanding and owned directly by FMCH. Such 18,312,735 shares of Common Stock exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement described in the initial Schedule 13D, and FME AG and FMCH disclaim any present beneficial ownership of any such additional shares.

**(b)**
As the record owner of the 18,312,735 shares of Common Stock reported in this Schedule 13D (Amendment No 7), FMCH possesses voting and dispositive power over such shares. FME AG is the indirect sole shareholder of FMCH and may be deemed to be a beneficial owner of such shares.

**(c)**
The decrease in the percentage beneficial ownership reported herein from 9.5%, as reported in Schedule 13D (Amendment No. 6) to 8.4%, as reported herein, results solely from an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of Amendment No. 6 to this Schedule 13D, as described in Item 5(a). Neither FME AG nor FMCH has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of their initial Schedule 13D in September 2021.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fresenius Medical Care Holdings, Inc.

**Signature:** /s/ Bryan Mello

**Name/Title:** Bryan Mello, Asst. Treasurer

**Date:** 03/24/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fresenius Medical Care AG

**Signature:** /s/ ppa Dr. Angela Koelbl

**Name/Title:** Dr. Angela Koelbl, Registered Manager (Prokurist)

**Date:** 03/24/2026